BridgeBio Pharma, a Palo Alto, CA-based clinical-stage biopharmaceutical company, raised an additional $135m in funding.
The round was co-led by new investor Viking Global Investors and existing investor KKR with participation from existing investor Perceptive Advisors and new investors AIG, Aisling Capital, Cormorant Capital and Janus Funds.
The company intends to use the funds to advance its existing programs and establish novel efforts.
Founded in 2015 by Neil Kumar, Ph.D., chief executive officer, and Frank McCormick, Ph.D., a professor in the UCSF Helen Diller Family Comprehensive Cancer Center and former scientific co-founder of Onyx Pharmaceuticals, BridgeBio is a clinical-stage biotech company developing genetically targeted therapies, in various phases of development, from pre-clinical to late-stage.
To date, the company has launched ten drug programs under its dermatology, oncology, cardiology, neurology and endocrine business units. Targeted indications include transthyretin amyloidosis (ATTR-CM and ATTR-PN), pantothenate kinase-associated neurodegeneration (PKAN), Gorlin syndrome and frequent basal cell carcinomas, dystrophic epidermolysis bullosa (DEB), Darier and Hailey-Hailey diseases, Netherton syndrome, and SHP-2, K-RAS and C-RAF driven cancers.